CorMedix Inc expected to post earnings of 13 cents a share - Earnings Preview

CorMedix

07/03/2025 13:15

CorMedix Inc CRMD.OQ CRMD.O is expected to show a rise in quarterly revenue when it reports  results on March 10 (estimated) for the period ending December 31 2024

The Berkeley Heights New Jersey-based  company is expected to report revenue of $25.414 million, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on January 7 2025, for the period ended December 31, was for revenue of $31.000 million.

​LSEG's mean analyst estimate for CorMedix Inc is for earnings of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for CorMedix Inc is $17.00​, above​ its last closing price of $9.49. ​​​

The company's guidance on January 7 2025 for the period ended December 31 was for Earnings before Interest, Taxes, Depreciation and Amortization of of USD12 million.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.10
-0.10
-0.05
Beat
51.3
Jun. 30 2024
-0.24
-0.25
-0.25
Met
0
Mar. 31 2024
-0.27
-0.28
-0.25
Beat
9.9​
Dec. 31 2023
-0.20
-0.20
-0.26
Missed
-28.9
​​Sep. 30 2023
-0.20
-0.21
-0.17
Beat
18.2
Jun. 30 2023
-0.23
-0.24
-0.25
Missed
-3.6​
Mar. 31 2023
-0.20
-0.20
-0.24
Missed
-20
Dec. 31 2022
-0.19
-0.20
Missed
-7

This summary was machine generated March 7 at 13:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)